| Earnings Preview: Merck Zacks.com submits: Merck (MRK) is scheduled to release its first quarter 2010 earnings on May 4, 2010. The company is expected to earn 75 cents during the quarter, according to the Zacks Consensus Estimate. The company is expected to provide its outlook for 2010 along with first quarter results.Previous Quarter HighlightsComplete Story » seekingalpha.com |
Highlights of the RESILIENT Trial - Video TRIAL DATA DEMONSTRATES BARD LifeStent® VASCULAR STENT IS SUPERIOR TO ANGIOPLASTY FOR LESIONS IN SUPERFICIAL FEMORAL ARTERY AND PROXIMAL POPLITEAL ARTERY feedproxy.google.com |
A Delay in Protalix's Uplyso FDA Review Is Not a Disaster EP Vantage submits:Unlike the World Cup, in the race to get a product on the market in an orphan indication there are no silver or bronze medals, only a standard 10-month regulatory review period. This is what Protalix (PLX) has learned as the FDA handed it a standard review, with a February 25, 2011, PDUFA date, for the Gaucher’s disease drug Uplyso.With the continued uncertainty over the supply of Genzyme’s (GENZ) Cerezyme (Genzyme moves on but faces uncertain future, May 25, 2010), many observers had been expecting an expedited review for Uplyso. However, the entrance of Shire’s (SHPGY) Vpriv into the marketplace may be filling the gap. With Genzyme having told analysts and investors that Cerezyme production will slowly increase from current 50% levels in late summer, perhaps the FDA believed market demand was being met and another expedited review was unnecessary.Complete Story » seekingalpha.com |
J&J Seeks Remicade Damages Johnson & Johnson is seeking damages from Merck as it negotiates to dissolve a partnership over the big-selling rheumatoid arthritis drug Remicade. online.wsj.com |
Santarus: Building a New Company on Zegerid’s Ashes By Larry SmithInvestors are evaluating the impact on the earnings of Santarus (NASDAQ:SNTS) following the recent launch of a generic to its key product Zegerid. Of perhaps more importance, they are also trying to gauge how much and when a pipeline of new in-licensed products can bolster sales and earnings. The remainder of this year and first half of 2011 will be muddled because of year over year comparisons to quarters in which Zegerid had not been hit by a generic competitor. Complete Story » seekingalpha.com |